These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 24291818)

  • 1. Molecular insights on TNKS1/TNKS2 and inhibitor-IWR1 interactions.
    Kirubakaran P; Kothandan G; Cho SJ; Muthusamy K
    Mol Biosyst; 2014 Feb; 10(2):281-93. PubMed ID: 24291818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The binding mechanism of a novel nicotinamide isostere inhibiting with TNKSs: a molecular dynamic simulation and binding free energy calculation.
    Feng TT; Zhang YJ; Chen H; Fan S; Han JG
    J Biomol Struct Dyn; 2016; 34(3):517-28. PubMed ID: 25933061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence for tankyrases as antineoplastic targets in lung cancer.
    Busch AM; Johnson KC; Stan RV; Sanglikar A; Ahmed Y; Dmitrovsky E; Freemantle SJ
    BMC Cancer; 2013 Apr; 13():211. PubMed ID: 23621985
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Loganathan L; Muthusamy K; Jayaraj JM; Kajamaideen A; Balthasar JJ
    J Biomol Struct Dyn; 2019 Sep; 37(14):3637-3648. PubMed ID: 30204055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insights of tankyrases: A novel target for drug discovery.
    Damale MG; Pathan SK; Shinde DB; Patil RH; Arote RB; Sangshetti JN
    Eur J Med Chem; 2020 Dec; 207():112712. PubMed ID: 32877803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of new dual binding TNKS inhibitors of Wnt signaling inhibition by pharmacophore modeling, molecular docking and bioassay.
    Pu Y; Zhang S; Chang Z; Zhang Y; Wang D; Zhang L; Li Y; Zuo Z
    Mol Biosyst; 2017 Jan; 13(2):363-370. PubMed ID: 27995250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of novel dual binders as potent, selective, and orally bioavailable tankyrase inhibitors.
    Hua Z; Bregman H; Buchanan JL; Chakka N; Guzman-Perez A; Gunaydin H; Huang X; Gu Y; Berry V; Liu J; Teffera Y; Huang L; Egge B; Emkey R; Mullady EL; Schneider S; Andrews PS; Acquaviva L; Dovey J; Mishra A; Newcomb J; Saffran D; Serafino R; Strathdee CA; Turci SM; Stanton M; Wilson C; Dimauro EF
    J Med Chem; 2013 Dec; 56(24):10003-15. PubMed ID: 24294969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel binding mode of a potent and selective tankyrase inhibitor.
    Gunaydin H; Gu Y; Huang X
    PLoS One; 2012; 7(3):e33740. PubMed ID: 22438990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New molecular insights for 4
    Mehta CC; Rohit S; Patel S; Bhatt HG
    J Biomol Struct Dyn; 2023; 41(22):13496-13508. PubMed ID: 36755438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insights into the binding of PARP inhibitors to the catalytic domain of human tankyrase-2.
    Qiu W; Lam R; Voytyuk O; Romanov V; Gordon R; Gebremeskel S; Vodsedalek J; Thompson C; Beletskaya I; Battaile KP; Pai EF; Rottapel R; Chirgadze NY
    Acta Crystallogr D Biol Crystallogr; 2014 Oct; 70(Pt 10):2740-53. PubMed ID: 25286857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disruption of Wnt/β-Catenin Signaling and Telomeric Shortening Are Inextricable Consequences of Tankyrase Inhibition in Human Cells.
    Kulak O; Chen H; Holohan B; Wu X; He H; Borek D; Otwinowski Z; Yamaguchi K; Garofalo LA; Ma Z; Wright W; Chen C; Shay JW; Zhang X; Lum L
    Mol Cell Biol; 2015 Jul; 35(14):2425-35. PubMed ID: 25939383
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Liu J; Feng K; Ren Y
    J Biomol Struct Dyn; 2019 Sep; 37(14):3803-3821. PubMed ID: 30261821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 2-Phenylquinazolinones as dual-activity tankyrase-kinase inhibitors.
    Nkizinkiko Y; Desantis J; Koivunen J; Haikarainen T; Murthy S; Sancineto L; Massari S; Ianni F; Obaji E; Loza MI; Pihlajaniemi T; Brea J; Tabarrini O; Lehtiö L
    Sci Rep; 2018 Jan; 8(1):1680. PubMed ID: 29374194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tankyrase Sterile α Motif Domain Polymerization Is Required for Its Role in Wnt Signaling.
    Riccio AA; McCauley M; Langelier MF; Pascal JM
    Structure; 2016 Sep; 24(9):1573-81. PubMed ID: 27499439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors.
    Wahlberg E; Karlberg T; Kouznetsova E; Markova N; Macchiarulo A; Thorsell AG; Pol E; Frostell Å; Ekblad T; Öncü D; Kull B; Robertson GM; Pellicciari R; Schüler H; Weigelt J
    Nat Biotechnol; 2012 Feb; 30(3):283-8. PubMed ID: 22343925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sighting of tankyrase inhibitors by structure- and ligand-based screening and in vitro approach.
    Kirubakaran P; Arunkumar P; Premkumar K; Muthusamy K
    Mol Biosyst; 2014 Oct; 10(10):2699-712. PubMed ID: 25091558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural insights into SAM domain-mediated tankyrase oligomerization.
    DaRosa PA; Ovchinnikov S; Xu W; Klevit RE
    Protein Sci; 2016 Sep; 25(9):1744-52. PubMed ID: 27328430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of Epstein-Barr virus OriP function by tankyrase, a telomere-associated poly-ADP ribose polymerase that binds and modifies EBNA1.
    Deng Z; Atanasiu C; Zhao K; Marmorstein R; Sbodio JI; Chi NW; Lieberman PM
    J Virol; 2005 Apr; 79(8):4640-50. PubMed ID: 15795250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The zinc-binding motif in tankyrases is required for the structural integrity of the catalytic ADP-ribosyltransferase domain.
    Sowa ST; Lehtiö L
    Open Biol; 2022 Mar; 12(3):210365. PubMed ID: 35317661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent advances in the structure-based rational design of TNKSIs.
    Zhan P; Song Y; Itoh Y; Suzuki T; Liu X
    Mol Biosyst; 2014 Nov; 10(11):2783-99. PubMed ID: 25211064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.